Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Capital Expenditures (2017 - 2025)

Q32 Bio (QTTB) has 9 years of Capital Expenditures data on record, last reported at -$506000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures fell 972.41% year-over-year to -$506000.0; the TTM value through Sep 2025 reached $783000.0, up 59.8%, while the annual FY2024 figure was $856000.0, 102.84% up from the prior year.
  • Capital Expenditures reached -$506000.0 in Q3 2025 per QTTB's latest filing, down from $259000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.4 million in Q4 2021 and bottomed at -$723000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $261000.0, with a median of $58000.0 recorded in 2024.
  • The widest YoY moves for Capital Expenditures: up 5700.0% in 2024, down 9900.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $2.4 million in 2021, then crashed by 99.62% to $9000.0 in 2022, then skyrocketed by 4533.33% to $417000.0 in 2023, then skyrocketed by 87.77% to $783000.0 in 2024, then crashed by 164.62% to -$506000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$506000.0 in Q3 2025, $259000.0 in Q2 2025, and $247000.0 in Q1 2025.